Bydureon is a prescription medication that is used along with diet and exercise to treat type 2 diabetes. Bydureon belongs to a group of medications called incretin mimetics which work by helping the pancreas to secrete insulin when blood sugar levels are high. They also decrease the amount of sugar the liver produces and slow the emptying of the stomach.
Common side effects of Bydureon include nausea, vomiting, diarrhea, and low blood sugar.
WARNING: RISK OF THYROID C-CELL TUMORS
- Bydureon causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether Bydureon causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies.
- Bydureon is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Bydureon. Patients should be counseled regarding the risk and symptoms of thyroid tumors.
